BMS-986325 ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 53 | Sjogren syndrome | 1 |
53. Sjogren syndrome
Clinical trials : 305 / Drugs : 325 - (DrugBank : 104) / Drug target genes : 58 - Drug target pathways : 188
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04684654 (ClinicalTrials.gov) | February 16, 2021 | 22/12/2020 | BMS-986325 in Healthy Participants and Participants With Primary Sjögren's Syndrome | A Double-Blind, Placebo-Controlled, Randomized, Single and Multiple Dose Study on the Safety, Pharmacokinetics, and Exploratory Pharmacodynamics of Subcutaneous and Intravenous BMS-986325 Administration in Healthy Participants and Participants With Primary Sjögren's Syndrome | Healthy Participants;Primary Sjögren's Syndrome | Biological: BMS-986325;Other: Placebo for BMS-986325 | Bristol-Myers Squibb | NULL | Recruiting | 18 Years | 75 Years | All | 136 | Phase 1 | United States;Germany |